Back to Search Start Over

Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETS): an Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro Il Cancro Del Polmone)

Authors :
Marco Angelo Burgio
Antonio Santo
G. Genestreti
S. Sanna
Luca Ampollini
A. Verlicchi
Giampaolo Gavelli
Roberta Buosi
Manlio Monti
M. Mezzetti
Source :
Annals of Oncology. 23:ix496-ix497
Publication Year :
2012
Publisher :
Elsevier BV, 2012.

Abstract

Purpose thymic epithelial tumors (TETs) are a rare neoplasms. Due to their rarity, large-scale prospective trials are lacking. The present retrospective multicenter analysis aimed to evaluate clinical outcome and clinical-pathological features of TETs after complete surgical resection and adjuvant treatments (Adj) such as chemotherapy (CHT) or radiotherapy (RT). Patients and methods Patients who underwent a complete surgical resections for TETs between 2000 and 2007 were reviewed. WHO histological classification criteria and Masaoka staging system were used. Adj were: anthracycline- and platin-based CHT, RT on irradiation fields covering the primary tumor bed. Overall survival (OS) was calculated from the date of diagnosis until patient death or last follow-up visit. Disease free-survival (DFS) was defined as the interval between surgery and date of first documentation of recurrence. OS, DFS and 95% Confidence Interval (95% CI) were estimated by Kaplan-Meier method. Results 62 patients were analyzed: 30 patients (48%) male and 32 (52%) female. Median age was 60 years (range: 33 - 86). At the beginning of their cancer history 20 (32%) patients had myasthenia. Clinical staging showed: 31 (50%) stage I disease, 19 (30%) stage II, 5 (8%) stage III, 2 (4%) stage IVa, 5 (8%) stage IVb. Histologies were: 11 (19%) A tumor type, 18 (29%) AB type, 7 (12%) B1 type, 11 (17%) B2 type, 11 (17%) B3 type and 3 (6%) C type. Pathological staging were: 30 (48%) stage I, 22 (35%) stage II, 3 (6%) stage III, 2 (3%) stage IVa, 5 (8%) stage IVb. 3 (5%) patients received Adj-CHT and 16 (26%) Adj-RT. Median follow-up was 71 months (range 1-145), DFS and OS are the following: % DFS (95% CI) % OS (95% CI) Events 48 mo 60 o0 72 mo Events 48 mo 60 mo 72 mo 9 89 (80-97) 89 (80-97) 86 (76-96) 7 97 (92-100) 95 (88-100) 92 (85-100) mo, months. Conclusions TETs are rare and indolent tumors. Surgery offers good results which can be further improved by Adj such as CHT and/or RT. Supported by GIPO. Disclosure All authors have declared no conflicts of interest.

Details

ISSN :
09237534
Volume :
23
Database :
OpenAIRE
Journal :
Annals of Oncology
Accession number :
edsair.doi...........8960c1778630daeabfdaf962f11ad5a5